# NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

> **NCT01870427** · PHASE4 · COMPLETED · sponsor: **Northern California Retina Vitreous Associates** · enrollment: 20 (actual)

## Conditions studied

- Macular Edema With Central Retinal Vein Occlusions

## Interventions

- **DRUG:** Aflibercept (2.0 mg)

## Key facts

- **NCT ID:** NCT01870427
- **Lead sponsor:** Northern California Retina Vitreous Associates
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-08
- **Final completion:** 2016-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2016-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01870427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01870427, "NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01870427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*